01 نوفمبر #advanced melanoma #BRAF inhibitor #case report #MEK inhibitions Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report by Dr. Fadi Farhat 0
10 أغسطس #advanced #cisplatin #first-line therapy #maintenance #non-small cell lung cancer #Oral #vinorelbine Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer by Dr. Fadi Farhat 0
29 ديسمبر #advanced #Cancer #FOLFOX-6 #gemcitabine #locally #metastatic #Pancreatic #sequential Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer by Dr. Fadi Farhat 0
06 سبتمبر #advanced #Cancer #carboplatin #first-line #gemcitabine #paclitaxel #sequential #therapy #treatment #urothelial Sequential therapy with gemcitabine and Carboplatin followed by Paclitaxel as first-line treatment for advanced urothelial cancer by Dr. Fadi Farhat 0
28 أبريل #advanced #Cancer #capecitabine #combination #gastric #irinotecan #metastatic #role #therapy Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer by Dr. Fadi Farhat 0
07 أبريل #advanced #capecitabine #combination #gastric cancer #irinotecan #metastatic #role #therapy Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer by Dr. Fadi Farhat 0
21 يونيو #advanced #breast cancer #capecitabine #Docetaxel #long-term #Phase II #pilot #sequential #trial #vinorelbine Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial. by Dr. Fadi Farhat 0
14 يناير #advanced #Chemotherapy #Docetaxel #first-line #irinotecan #NSCLC #patients #pilot #study Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study by Dr. Fadi Farhat 0
02 فبراير #first-line #FOLFOX-6 #locally advanced #metastatic pancreatic cancer FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer by Dr. Fadi Farhat 0
